AZ-BLUE-YONDER
2.7.2024 10:01:31 CEST | Business Wire | Press release
The cosmetics industry is experiencing continued growth as consumers worldwide increasingly prioritize self-care and wellness. However, this growth has also led to a more competitive landscape, and companies must make strategic choices to differentiate themselves and maintain success in this dynamic market. That is why Avon International chose Blue Yonder Platform with Cognitive Demand Planning, Enterprise Supply Planning and Control Tower solutions to create an end-to-end next generation supply chain and support the company’s strategy and vision.
Avon International is a global beauty company operating in over 40 countries across Europe and Asia Pacific. The brand Avon has been in operation for over 135 years and has a business model based on relationship selling. Millions of independent representatives offer personalised beauty advice to their customers through offline and online channels. The brand is also accessed through wholesalers, retail stores and marketplaces.
Avon International was seeking to optimize its manufacturing and distribution processes in both Europe and Asia Pacific by establishing a "Planning Hub" for centralized demand and supply planning. To streamline demand planning, respond more quickly to their dynamic market and enhance decision-making, Avon International selected Blue Yonder’s flexible SaaS supply chain solutions, based on advanced artificial intelligence (AI) and machine learning (ML) capabilities.
“Avon International is committed to transforming itself to meet the needs of its customers, Representatives and partners while staying true to its business model and values. To support this global transformation across all channels, Avon International recognized the need for a more integrated approach to demand planning. After a thorough selection process, Blue Yonder was chosen for its comprehensive solutions and innovative capabilities that met all of Avon International’s needs. With Blue Yonder’s supply chain solutions, powered by leading-edge AI and ML capabilities, Avon International will be empowered to meet the changing needs of its customers, representatives, and partners in a profitable and sustainable way,” said Maciej Kaniowski, COO, Avon International.
The need to reduce inventory across the company has made accurate forecasting and efficient demand planning a business imperative. Blue Yonder solutions’ key differentiators include not only the robustness, experience, and scalability of ML forecasting, but also the extensibility and explainability of causal factors, that for Avon include campaigns, price, promotions, catalogue position, and seasonality.
These factors train Blue Yonder’s ML models to predict future demand. Blue Yonder’s explainability and scenario composable services help planners understand causal contributions and run simulations based on changes like price or promotions, resulting in superior accuracy, greater explainability, and improved decision-making.
Once the Blue Yonder solutions are implemented, Avon International will be able to drive supply chain process simplification and achieve the following benefits:
- Streamline operations with an integrated, end-to-end planning process for managing trends, demand, supply, inventory, and vendor collaboration.
- Surpass forecast accuracy and achieve improved planner efficiency with the configuration of Avon’s causal factors.
- Expand omni-channel capabilities and gain a competitive edge by forecasting and planning for all channels and offer types in one solution.
- Improve service levels and optimize cash flow with a comprehensive forecasting and planning solution that supports a centralized planning hub.
Avon International’s manufacturing supply chain operations in Europe and Asia Pacific are managed by Avon Operations Polska (AOP) and Avon Distribution Polska (ADP), with the backbone of their activities located in Garwolin, Poland. AOP manages the largest and most technologically advanced Avon factory worldwide. Cosmetics manufactured here are distributed to approximately 40 countries on three continents.
"We are thrilled to be a part of Avon International’s supply chain digital transformation. It is an honor to work with a company that shares our same commitment to values such as inclusion, women empowerment, and equity. The Blue Yonder solutions will enable Avon International to adapt to changing market conditions and external dynamics, ensuring their supply chain remains agile, sustainable, and competitive," said Terry Turner, president, Manufacturing, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder Cognitive Demand Planning
- Video: Next Generation Demand Planning with Cognitive Demand Planning
- Learn more about: Blue Yonder Solutions for Consumer Industries
- E-book: Improving the Supply Chain through Predictive Insight
About Avon
At Avon, we believe a better world for women is a better world for all. We are the beauty brand for women embracing their power, inspiring their confidence and providing opportunities to realise their potential. Millions of independent sales Representatives across the world sell iconic Avon brands through their social networks and more than 20% of every sale helps to create better futures for women*. We stand for progress for women: we believe in listening to women’s needs, speaking out about issues that matter and creating positive change. Through Avon and the Avon Foundation, we have donated over $1.1 billion, with a focus on tackling gender violence and breast cancer. Avon is part of the Natura &Co Group.
*Learn more at www.avonworldwide.com.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240702770779/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
